Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley
CEO, Dr Jackie Fairley
Source: Starpharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totalling more than $2 million for Vietnam
  • On December 1, the company announced its nasal spray was registered for sale in Vietnam with a formal launch attended by clinicians, politicians and healthcare workers
  • VIRALEZE works by slowing down the infection of host cells when applied to cells before and after exposure to a respiratory virus
  • VIRALEZE is now available in Vietnamese hospitals, clinics, pharmacies and retail consumers via local medical distribution networks
  • Starpharma is down a slight 0.40 per cent on the market with shares trading at $1.26

Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totalling more than $2 million for Vietnam.

On December 1, the company announced its nasal spray was registered for sale in Vietnam with the formal launch attended by clinicians, healthcare professionals, politicians and media representatives.

Starpharma’s VIRALEZE nasal spray contains antiviral agent SPL7013, which works by slowing down the infection of host cells when applied to cells before and after exposure to respiratory viruses.

From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.

CEO Jackie Fairley is delighted with the success already achieved.

“We are delighted that the launch of VIRALEZE in Vietnam was so successful and has already generated significant sales,” Dr Fairley commented.

“This demand is indicative of the significant need for products like VIRALEZE, which are complimentary to vaccines and other preventative strategies.”

VIRALEZE is now available in Vietnamese hospitals, clinics, pharmacies and retail consumers via local medical distribution networks.

Starpharma said it continues negotiations with potential commercial partners elsewhere in multiple countries in Europe, Asia, and the Middle East.

Starpharma was down a slight 0.40 per cent on the market, with shares trading at $1.26 at 12:21 pm AEDT.

SPL by the numbers
More From The Market Online

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think…
The Market Online Video

Market Close: ASX signs off on a sigh with all sectors red-lining

The ASX200 finished 1.3 per cent down with every sector in the red and Industrials and Real Estate brittle and bruised as bot…
The Market Online Video

Market Update: ASX on red alert with all sectors below the surface

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.